Clinical Trial Update: The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating whether concurrent oral calcium carbonate affects steady-state pharmacokinetics of oral raltegravir in HIV patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Calcium carbonate (Calcium carbonate)
• Raltegravir (raltegravir)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Calcium Supplementation in HIV Patients Using Raltegravir | Phase 4 | Status: UNKNOWN